Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01278-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Mark M Hahn und 11 weiteren Autor:innen. Beteiligte Einrichtung: Battelle, West Jefferson, Ohio, USA. Hauptthemen laut MEDLINE: Tularemia, Cephalosporins, Anti-Bacterial Agents, Francisella tularensis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Health and Human Services, Basilea Pharmaceutica.
Abstract (Originalsprache)
Francisella tularensis is the etiologic agent of tularemia, and there are few FDA-approved antibiotics to treat infections. Ceftobiprole medocaril has potential for being developed as a therapeutic for the treatment of inhalational tularemia, as it has previously demonstrated efficacy in vivo . Pharmacokinetic modeling of ceftobiprole in cynomolgus macaques was used to predict an efficacious dose of ceftobiprole medocaril against inhalational tularemia in the disease model based on the measured exposures and human clinical exposure data. The efficacy of ceftobiprole medocaril against inhalational tularemia was then evaluated in the cynomolgus macaque disease model using three doses designed to mimic the human mean clinical exposure of ceftobiprole medocaril (including the predicted efficacious dose). Treatments of 0.00 (placebo), 1.33, 6.67, or 20.0 mg/kg ceftobiprole medocaril (q8h for 10 days) were administered to cynomolgus macaques by intravenous infusion after animals were exposed to aerosolized F. tularensis and exhibited a fever. Control animals exhibited a 12.5% survival rate, a median time to death of 11.63 days post-challenge, and significantly elevated tissue burdens. By comparison, animals receiving 1.33 mg/kg treatments with ceftobiprole medocaril exhibited a 50% survival rate, and animals receiving either of the higher doses exhibited an 87.5% survival rate. Evidence of adaptive immunity (seroconversion) was identified in all surviving animals, though detection of F. tularensis with sensitivity to ceftobiprole in vitro in a limited number of treated and surviving animals indicates that the clinical efficacy of ceftobiprole medocaril may be enhanced by treatment durations greater than 10 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Battelle, West Jefferson, Ohio, USA.
- Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.
ORCID-Profile: Mark M Hahn, Michael S Anderson, Matthew Snyder, Jennifer I Smart, Karine Litherland
Förderung
- U.S. Department of Health and Human Services
- Basilea Pharmaceutica
Zitieren
APA
Hahn, M. M., Anderson, M. S., Snyder, M., Du, W., Chou, Y. L., McCracken, B., Smart, J. I., Litherland, K., Keech, S., von Siebenthal, F., Jones, M., & Henning, L. N. (2025). Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01278-25
Vancouver
Hahn MM, Anderson MS, Snyder M, Du W, Chou YL, McCracken B, et al. Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01278-25
BibTeX
@article{Hahn2025,
author = {Hahn, Mark M and Anderson, Michael S and Snyder, Matthew and Du, Wantong and Chou, Ying-Liang and McCracken, Brent and Smart, Jennifer I and Litherland, Karine and Keech, Stephen and von Siebenthal, Franziska and Jones, Mark and Henning, Lisa N},
title = {Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01278-25}
}
EUVIMED